NextGen Omics, Tech & Data Europe 2026
Congress Centre Basel, Switzerland
Programme
Day
Integrating Xenium Spatial Transcriptomics Into Preclinical Research for High-Resolution Molecular Profiling
Industry PresentationSpatial transcriptomics is transforming preclinical research by enabling the high-resolution mapping of gene expression within intact tissue architecture. The Xenium platform introduces a next-generation approach to in situ transcriptomic profiling, combining high sensitivity, subcellular resolution, and scalable multiplexing to interrogate complex biological systems.
We will present how Xenium Spatial Transcriptomics is being integrated into preclinical research workflows to deliver precise molecular insights across diverse application areas. By preserving spatial context while quantifying hundreds to thousands of RNA targets simultaneously, Xenium allows researchers to resolve cellular heterogeneity, identify rare cell populations, and characterise cell–cell interactions within their native microenvironment.
Twist Biosciences Presentation
Solution Provider PresentationA Translational Journey To Pancreatic Cancer Detection
Industry PresentationThis talk presents the translational journey of urinary biomarkers for early detection of pancreatic cancer, from proteomics discovery through large-scale validation to laboratory test development. It highlights the path to clinical implementation via ProcyonDx, demonstrating the potential of non-invasive diagnostics to transform early detection and improve outcomes in this deadly disease.
Illumina Presentation
Solution Provider PresentationNavinci Presentation
Solution Provider PresentationSingle Cell Transcriptome Heterogeneity
Industry PresentationBio-Techne Spatial Presentation
Solution Provider PresentationMembranes, Proximities, and Clones: Unlocking Multi-scale Spatial Biology for AI-Driven Precision Oncology
Industry PresentationComputational pathology transforms standard immunohistochemistry into multi-scale spatial biology. We demonstrate how quantitative continuous scoring (QCS) extracts sub-cellular features such as membrane-to-cytoplasm staining intensity ratios, cell-neighborhood proximities, and clone-level tumor heterogeneity maps from single tissue sections. We illustrate how this framework has been applied in oncology clinical trials to derive predictive biomarkers and support companion diagnostic development—culminating in a first implementation proof-point of AI-driven precision medicine.
10x Genomics Presentation
Solution Provider PresentationPredicting Cell Fate Decisions From Longitudinal Single-Cell Transcriptomics In Paediatric Acute Myeloid Leukaemia Patients
Industry PresentationZeiss Presentation
Solution Provider PresentationSingular Genomics Presentation
Solution Provider PresentationSingle Cell & Spatial Bioinformatics To Identify New Targets In Rheumatoid Arthritis
Industry PresentationMulti-Omics: What is the Ask From Precision Medicine?
Industry Presentation- A Pivotal Need
- What is Real?
- Around the World: coming full circle
Leica Microsystems Presentation
Industry PresentationUtilising Spatial Biology In Pharma R&D
Panel Discussion• Enhancing precision medicine in drug research
• Bridging research to clinical applications
• Facilitating Academia &
• Industry collaboration
Translating Omics Data To Clinical Trial Decisions
Panel Discussion• Ensuring clinical developments in under-represented therapeutic areas
• When does omics data become robust enough to influence trial design
• Cross functional team requirements for success
From Spatial Biology to Therapeutic Insight: Lessons from Alzheimer’s Disease and Oncology
Industry PresentationWe leverage high-resolution spatial transcriptomics to decode tissue microenvironments and understand new therapies. In clinical oncology, we use paired immunotherapy biopsies to map cellular niche evolution post-treatment. In preclinical neuroscience, we dissect Alzheimer’s plaque niches to uncover cell-specific interferon signatures. Together, these spatial insights drive biomarker discovery and tailored, next-generation treatments.
Vizgen Presentation
Solution Provider PresentationDECIPHERing Genomic Data: Applying FAIR Principles & Standards for Clinical Impact
Industry Presentation- Explore how FAIR data principles and community standards drive translation of research to clinical applications.
- Learn how global initiatives like the Global Alliance for Genomics and Health enable broad, responsible use of genomic data.
- Hear how DECIPHER exploits standards to provide real-world tools for advancing clinical discovery and patient benefit.
Population-Scale Single-Cell Atlasing for Next-Generation Blood Diagnostics
Industry PresentationSingle-cell genomics offers unprecedented resolution in blood diagnostics with potential for mechanistic understanding into underlying causes of blood abnormalities.
Population-scale single-cell atlases of human blood spanning ~6,000 individuals across multiple biobanks lay the groundwork for next-generation blood diagnostics and for detecting outlier phenotypes across tissues beyond blood
Turning Single Cell Insights Into Novel Targets
Panel DiscussionHow to best use multi-omics data to gain new insights
Developing single cell and spatial data results into actional targets and biomarkers
Utilising rare single cells
N6 Presentation
Solution Provider PresentationPractical Application of Single-Cell Technologies for Large Molecule Drug Development
Industry Presentation- A highlight of practical applications of single-cell technologies along the drug development pipeline
- Developing atlases to accelerate target ID and functional validation
- Moving past RNA to direct protein quantification on cells
Roche Diagnostic Solutions Presentation
Solution Provider PresentationOvercoming Computational Challenges of Bioinformatics In Single Cell & Spatial Research
Panel Discussion• Application of advanced AI models to complex bioinformatics challenges
• Integration and optimisation of deep learning methodologies
• Ensuring high standards of accuracy, computational efficiency, and interpretability in analytical outcomes
Aspect Analytics Presentation
Solution Provider PresentationCellCarta Presentation
Solution Provider PresentationSingle Cell Discoveries Presentation
Solution Provider PresentationOne Graph To Rule Them All: Universal “Tree-Of-Life” Pangenomes
WorkshopFractal-based pangenome graphs eliminate dependence on static reference genomes, enabling a single immutable graph to represent all individuals across all species. This tree-of-life structure provides universal coordinates compatible with BAM files, removing the need for species-specific, individual-specific, or chromosome-specific references in genomic analyses.
RareCyte Presentation
Solution Provider PresentationSingle Cell Omics To Understand The Role Of The Placenta In Preeclampsia
Industry PresentationCytosurge Presentation
Solution Provider PresentationMiltenyi Biotec Presentation
Solution Provider PresentationFrom Undruggable to Actionable: Transcriptomic Discovery of Small-Molecule Modulators of Oncogenic Transcription Factors
Industry PresentationQUANTRO developed a Transcriptomic Discovery Platform that matches time-resolved transcriptional profiles triggered by small molecules with those from acute target degradation. This approach identifies direct inhibitors, modulators, and degraders of previously undruggable transcription factors and signaling nodes, with active discovery campaigns against c-MYC and YAP/TEAD.
Adoption Of AI In Cellular Pathology Clinical Workflows
Industry PresentationA system-wide transformation enabling whole slide imaging, standardisation, and enhanced collaboration across health boards in Wales.
Digitisation improved workflow efficiency through remote reporting, rapid case sharing, and better teaching and training.
AI integration, particularly in prostate, breast, and gastric pathology, demonstrated high diagnostic accuracy, reduced variability and improved efficiency in the process.
Large-scale deployment showed improved detection rates, reduced turnaround times, and increased diagnostic confidence.
Overall, AI acts as a decision-support tool, augmenting pathologists while highlighting the need for robust data, validation, and governance.
Unlocking Population Genomics With Large Scale Cohort Studies
Panel DiscussionPrecision Immunology Using Computational Workflows and Machine Learning
Industry Presentation*Using nf-core for scalable and reproducible pre-processing
*Deep learning for assessing the immune receptor repertoire
*Use cases in cancer and autoimmune diseases
From Space to Spatial: Shaping Cancer Immunotherapy with Spatial Omics
Industry PresentationNeural niches promote tumor progression by shaping an immunosuppressive tumor microenvironment (TME).
Stromal components are key determinants of response to cancer immunotherapy.
Intratumoral genetic heterogeneity may drive the formation of distinct immune ecosystems. Genetic heterogeneity within tumors may influence antigen presentation, cytokine production, and immune recognition.
Unlocking Novel Therapeutic Strategies Using Somatic Genomics
Industry PresentationSomatic mutations occur after conception and accumulate throughout our lifespan. This creates a massive genetic diversity among our cells and drives differential cellular responses to selective pressures. Some somatic mutations cause or drive vulnerability to disease, others have a protective effect. By assessing these mutations in human disease, Quotient is uncovering novel disease insights and therapeutic strategies.
Gene Regulatory Network Inference in Health and Disease
Industry PresentationDecoding gene regulatory networks (GRNs) from single-cell RNA-seq data reveals how transcription factors orchestrate cell identity and dysfunction. This talk presents computational approaches to GRN inference, benchmarking strategies, and applications across disease contexts offering insights into regulatory rewiring underlying complex conditions.
Translating Single-Cell Data to Mechanistic Insights for Pre-clinical Safety Assessment
Industry PresentationUse single-cell omics to identify the specific cell types/states driving pre-clinical observations and link them to pathways/MOT
Case studies where single-cell readout resolve uncertainty
How these mechanistic insights strengthen weight-of-evidence for safety assessment
Leveraging Population-Scale Genomics & Health Registers For Clinical Discovery
Keynote• FinnGen is a large-scale public–private partnership combining genomic data with longitudinal health registry
data from over 500,000 participants in Finland
• The Nordic health register system enables lifelong follow-up of healthcare events since the 1960s, providing
unique opportunities to study disease onset, progression, and outcomes the genetic characteristics of the Finnish
population, together with close collaboration between academia, biobanks, hospitals, and 15 international
pharmaceutical companies, enable novel insights into disease mechanisms and translational research
Meteor Biotech
Solution Provider PresentationUsing Large Precision Health Datasets to Support R&D Activities
Industry PresentationLeveraging Population-Scale Genomics & Health Registers For Clinical Discovery: FinnGen Case Study
Industry PresentationRevolune Presentation
Solution Provider PresentationUsing AI Models & Omics Data To Fill Knowledge Gaps & Predict Patient Response
Industry PresentationEnsuring AI Safety With Genomic Data
Industry PresentationRevolutionizing Multi-Omics With Artificial Intelligence
Panel Discussion• Changing ways of thinking with the
opportunities provided by AI
• What ‘unanswerable’ questions could be
reconsidered?
Data Governance & Large-Scale Cloud Platforms
Industry PresentationNygen Presentation
Solution Provider PresentationGlencoe Software Presentation
Solution Provider PresentationBioLizard Presentation
Solution Provider PresentationMulti-Omics and Longitudinal AI Models for Identifying Novel Targets in Chronic Disease and Aging
Industry PresentationWe present a longitudinal AI framework integrating multi-omics, human genetics, and real-world clinical data to identify novel therapeutic targets for chronic and aging-related diseases. The approach moves beyond static ICD-based phenotypes to uncover disease-driving biology, improve target prioritization, and reduce late-stage clinical failure in metabolic and multimorbid conditions.
Advancing BRD9 Targeted GlueTM Mechanism of Action in AML via Multi-Omics Approach
Industry PresentationAmphista therapeutics is developing a proprietary Targeted GlueTM technology which induces degradation by target-assisted E3 ligase recruitment. In this presentation, I will showcase how Amphista is applying multi-omics approaches for understanding degraders’ mode of action and validating clinical biomarkers. As an example, I will use Amphista’s clinical development candidate for AML targeting the epigenetic regulator BRD9.
Keeping Patients At The Centre Of Data-Driven Precision Medicine
Panel DiscussionUsing Clinical Data In Foundation Models
Industry Presentation
Close of Day One & Networking Drinks Reception
Morning Break & Refreshments
Lunch Break
Afternoon Break & Refreshments
End of Event
Lunch Break
Morning Break & Refreshments
No sessions found matching your filters.
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
.png?length=600&name=1.GenScriptCorporation_Logo_EN_Horizontal_FullColor%20(2).png){kind=logo}
.png?length=600&name=9eaa81ee-5bbe-4b99-86f7-23f16ccb27a8-2-5668375logo-PersonalisCorporateLogo-(2).png)
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
